The two academic authors of the article by Jayne et al., Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609, 1 request retraction of the article because, according ...

To the Editor: In the phase 3 GRADUATE trials of gantenerumab for early Alzheimer’s disease reported by Bateman et al. (Nov. 16 issue), 1 participants receiving gantenerumab had a greater decrease in ...

Explore this issue of The New England Journal of Medicine (Vol. 394 No. 22).

The optimal approach to early resuscitation in septic shock is unknown. Equipoise exists between the use of larger volumes of intravenous fluids to restore perfusion and the use of early vasopressor ...

Explore this issue of The New England Journal of Medicine (Vol. 394 No. 23).

Author: The SODa-BIC Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials GroupAuthor Info & Affiliations In this pragmatic, adaptive, double-blind, randomized trial ...

The authors describe the scientific foundations of a study implicating autoantibodies against interleukin-10 in persons with inflammatory bowel disease.

In 832 patients with rare genetic disease, a conclusive diagnosis was made for 160 patients (19.2%) with long-read genome sequencing and for 137 patients (16.5%) with standard-of-care testing.

Exagamglogene autotemcel (exa-cel) is a cell therapy in which autologous CD34+ hematopoietic cells are engineered through ex vivo clustered regularly interspaced short palindromic repeats–Cas9 editing ...

Every year, many millions of surgical patients worldwide are unnecessarily exposed to a higher-than-necessary risk of blood transfusion because they do not receive a single dose of tranexamic acid ...

Hemorrhagic shock remains the leading cause of preventable death after injury. 1 Over the past two decades, early administration of blood products has transformed care for patients with bleeding. The ...

Divergent approaches to psychedelics regulation have led to an environment in which patients, clinicians, and policymakers face conflicting expectations about access, safety, and clinical responsib ...